.png){kind=icon}
.png){kind=icon}
Return
COMPARISON OF THE EFFECTS OF ABELACIMAB, ASUNDEXIAN, AND MILVEXIAN ON MEDICAL DEVICE-INDUCED CLOTTING AND THROMBIN GENERATION IN VITRO
.png){kind=icon}
PRE
AI
X
J
J
DOI：10.1016/j.jtha.2026.08.002.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Medical devices, such as central venous catheters and mechanical heart valves (MHVs), are associated with an increased risk of thrombosis. Clotting on these devices is initiated via the contact system. Adsorbed factor (F) XII undergoes autoactivation and activates FXI, which then propagates coagulation. Abelacimab, asundexian, and milvexian are FXI or FXIa inhibitors that are currently undergoing or have completed Phase 3 evaluation.
Journal
IF:
5
Papers:
9.8K
Citations:
2.3W
Organization
Cited Papers